-
Mitsubishi Tanabe Pharma Canada Announces that Company’s Oral Treatment Formulation for Amyotrophic Lateral Sclerosis (ALS) has been Added to the Provincial Drug Plan in Alberta
-
Mitsubishi Tanabe Pharma Canada Announces that Company’s Oral Treatment Formulation for Amyotrophic Lateral Sclerosis (ALS) has been Added to the Provincial Drug Plan in Ontario
-
Mitsubishi Tanabe Pharma Canada Concludes Letter of Intent with pan-Canadian Pharmaceutical Alliance for prRADICAVA® Oral Suspension (Edaravone)
-
Mitsubishi Tanabe Pharma Canada is Proud to Support a New HCP Directed Program: How to Break the News in ALS/MND
-
Mitsubishi Tanabe Pharma Canada Announces New Leadership
-
Mitsubishi Tanabe Pharma Canada Receives Engagement Letter from pan-Canadian Pharmaceutical Alliance for prRADICAVA® Oral Suspension
-
Mitsubishi Tanabe Pharma Canada Announces prRADICAVA® (Edaravone) Oral Suspension Is Now Available in Canada for the Treatment of Patients with ALS
-
prRADICAVA® (Edaravone) Oral Suspension Receives Positive Recommendation from CADTH for the Treatment of Patients with ALS
-
prRADICAVA® (Edaravone) Oral Suspension Receives Positive Recommendation from INESSS for the Treatment of Patients With ALS
-
Mitsubishi Tanabe Pharma Canada Announces Canadian Authorization of prRADICAVA® (Edaravone) Oral Suspension for the Treatment of Patients with ALS